Synthekine Enters into a Collaboration Agreement with Sanofi to Develop Selective IL-10 Agonists for the Treatment of Inflammatory Diseases
Shots:
- The strategic collaboration was made to develop & commercialize IL-10 receptor agonists for inflammatory diseases to advance Synthekine’s multiple approaches to optimizing IL-10
- As per the agreement, both companies will jointly be responsible for the research activities up to a defined point of preclinical development following which, Sanofi will solely be responsible for the subsequent preclinical, clinical & commercial activities for IL-10 therapeutics
- Moreover, Synthekine will receive an up front payment of $40M and will be eligible to receive additional payments including potential preclinical, development, regulatory & commercial milestones plus tiered royalties
Ref: Synthekine | Image: Synthekine
Related News:- Sanofi Reports Dupixent’s (dupilumab) US Label Update for its Use in Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
